Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.
Smith MR, Dixon CB, Wang Y, Liu Y, D'Agostino R Jr, Ruiz J, Oliver G, Miller LD, Topaloglu U, Chan MD, Farris M, Su J, Mileham KF, Zhao D, Li W, Sexton T, Lycan T, Haas KM, Grayson JM, Xing F.
Smith MR, et al. Among authors: haas km.
Cancer Res. 2024 Dec 2;84(23):4002-4016. doi: 10.1158/0008-5472.CAN-24-0658.
Cancer Res. 2024.
PMID: 39250241